China Kintor's Covid drug candidate cuts hospital, death risk in trial

Published: Apr 6, 2022 4:44 AM

China's Kintor Pharmaceutical said on Wednesday its potential Covid-19 treatment proxalutamide effectively reduced the risk of hospitalisation and death in a clinical trial involving outpatients with mild to moderate symptoms.

The results came from a multi-national clinical trial with over 700 subjects across the world, mostly from the United States, recruited during April-December, 2021, who were given either proxalutamide or a placebo, the company said in a filing...

DCA approves Sinovac vaccine for children, Pfizer's Covid pill

WHO recommends Merck Covid pill for high-risk patients

Pfizer urged to sell more Covid pills to developing countries

Cheap version of Merck Covid pill to be made for poorer nations

Indonesia to begin local production of Covid-19 antiviral pills soon

Comments0

By posting a comment, you agree to our Commenting Terms and Conditions as stipulated in full here.

Do's and don'ts when posting comments in Malaysiakini

TERMS & CONDITIONS

Foul language, profanity, vulgarity, slanderous, personal attack, threatening, sexually-orientated comments or the use of any method of communication that may violate any law or create needless unpleasantness will not be tolerated. Antisocial behaviour such as "spamming" and "trolling" will be suspended. Violators run the risk of also being blocked permanently.

REPORT VIOLATORS

Please use the report feature that is available below each comment to flag offending comments for our moderators to take action. Do not take matters in your own hands to avoid unpleasant and unnecessary exchanges that may result in your own suspension or ban.

NOTICE

Our commenting system is still under development. We have taken note of feedback provided.

Subscriber-only space: